Kenya may soon make history in its healthcare journey, with the Kenyan government launching plans for the production and subsequent distribution of the first locally made vaccine by 2027.
This was revealed by the Health Cabinet Secretary Aden Duale on Monday, January 12, during a strategic meeting with the board and senior management of the Kenya BioVax Institute, where he reviewed progress made so far in the vaccine manufacturing initiative.
Duale termed the initiative as a critical milestone in the strengthening of the health system in Kenya and one of the important planks of the Universal Health Coverage programme championed by the government of Kenya.
“This visit has focused on key milestones such as the development towards the first local vaccine dose trial product that is to be rolled out by the end of 2026,” Duale said in a statement he posted on his social media accounts.
Facility Construction on Track
During this visit, the Health CS made it clear that the first phase of the BioVax manufacturing plant has been finished, and that the first stage of this project has been fully financed by the government.
He added that the institute has now entered the second phase of the project, which will cover the integration of systems and the installation of essential equipment, such as the fill and finish system that has to be installed for the production of vaccines.
‘He mentioned that the project has entered the second phase and that the
The Kenya BioVax Institute was founded in 2021 during the COVID-19 pandemic, as the continent realized the need for it to transform from a vaccine importer to a vaccine manufacturer. This came after there was a disruption in the vaccine supply chain globally.
“Regulatory Milestone Boosts Confidence
Duale mentioned that Kenya has achieved World Health Organization Maturity Level 3 status, a milestone in regulation achieved through collaborations between the Pharmacy and Poisons Board and the National Quality Control Laboratory.
As per CS, this status provides for domestic pharmaceutical manufacturing. It also improves international confidence in Kenya’s regulatory frameworks to make it an ideal regional location for vaccine and pharmaceutical production.
“This achievement positions Kenya well to promote both national and regional health security,” the official added.
Strategic Partnerships: Factors Driving Progress
The Health CS reported that this project is supported in terms of partnerships, particularly with the World Bank in the program called Regional Health Emergency Preparedness, Response and Resilience (HEPRRP). The project aims at improving health care systems, enhancing pharmaceutical manufacturing, and addressing public health emergencies.
In an interactive forum with staff members of BioVax, Duale covered the need for transparency and accountability in public service, with the values being a prerequisite for ensuring a people-centered healthcare system.
Less Imports, A Strong Health Security
Once established, the Kenya BioVax Institute is anticipated to make a meaningful contribution to lessening the country’s dependence on imported vaccines, enhancing overall national health security, and facilitating overall growth in line with the Government’s Bottom-Up Economic Transformation Agenda (BETA) endeavours.
This will be considered a turning point for the health sector in Kenya, as it will see Kenya join an increasing number of African countries investing in domestic vaccine manufacturing to protect their citizens against future healthcare crises.
